Evidence map›Paper›PMID 25496032›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2015

NFAT targets signaling molecules to gene promoters in pancreatic β-cells.

Michael C Lawrence, Nofit Borenstein-Auerbach, Kathleen McGlynn, Faisal Kunnathodi, Rauf Shahbazov, Ilham Syed, Mazhar Kanak, Morihito Takita, Marlon F Levy, Bashoo Naziruddin

Open access · greenAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Friend and foe: β-cell CaMolecular metabolism · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michael C LawrenceIslet Cell Laboratory (M.C.L., N.B.-A., F.K., R.S., I.S., M.T.), Baylor Research Institute, Dallas, Texas 75226; Department of Pharmacology (K.M.), University of Texas Southwestern Medical Center, Dallas, Texas 75390; Institute of Biomedical Studies (M.K.), Baylor University, Waco, Texas 76798; and Annette C. and Harold C. Simmons Transplant Institute (M.F.L., B.N.), Baylor University Medical Center, Dallas, Texas 75246.
Nofit Borenstein-Auerbach
Kathleen McGlynn
Faisal Kunnathodi
Rauf Shahbazov
Ilham Syed
Mazhar Kanak
Morihito Takita
Marlon F Levy
Bashoo Naziruddin
Baylor University · USBaylor University Medical Center · USThe University of Texas Southwestern Medical Center · US

Funding

MAP Kinse in Islet FunctionR01DK055310 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI COBB, MELANIE H. · 1998 to 2014
$3.4M
NIDDK NIH HHS R01 DK055310NIDDK NIH HHS R01 DK55310
6 · The paper itself

Abstract

Nuclear factor of activated T cells (NFAT) is activated by calcineurin in response to calcium signals derived by metabolic and inflammatory stress to regulate genes in pancreatic islets. Here, we show that NFAT targets MAPKs, histone acetyltransferase p300, and histone deacetylases (HDACs) to gene promoters to differentially regulate insulin and TNF-α genes. NFAT and ERK associated with the insulin gene promoter in response to glucagon-like peptide 1, whereas NFAT formed complexes with p38 MAPK (p38) and Jun N-terminal kinase (JNK) upon promoters of the TNF-α gene in response to IL-1β. Translocation of NFAT and MAPKs to gene promoters was calcineurin/NFAT dependent, and complex stability required MAPK activity. Knocking down NFATc2 expression, eliminating NFAT DNA binding sites, or interfering with NFAT nuclear import prevented association of MAPKs with gene promoters. Inhibiting p38 and JNK activity increased NFAT-ERK association with promoters, which repressed TNF-α and enhanced insulin gene expression. Moreover, inhibiting p38 and JNK induced a switch from NFAT-p38/JNK-histone acetyltransferase p300 to NFAT-ERK-HDAC3 complex formation upon the TNF-α promoter, which resulted in gene repression. Histone acetyltransferase/HDAC exchange was reversed on the insulin gene by p38/JNK inhibition in the presence of glucagon-like peptide 1, which enhanced gene expression. Overall, these data indicate that NFAT directs signaling enzymes to gene promoters in islets, which contribute to protein-DNA complex stability and promoter regulation. Furthermore, the data suggest that TNF-α can be repressed and insulin production can be enhanced by selectively targeting signaling components of NFAT-MAPK transcriptional/signaling complex formation in pancreatic β-cells. These findings have therapeutic potential for suppressing islet inflammation while preserving islet function in diabetes and islet transplantation.

Indexed as

Promoter Regions, GeneticAnimalsCell Line, TumorCell SurvivalDNAE1A-Associated p300 ProteinExtracellular Signal-Regulated MAP KinasesGlucagon-Like Peptide 1GlucoseHistone DeacetylasesHumansInsulinInsulin-Secreting CellsMiceMitogen-Activated Protein KinasesModels, BiologicalDNAE1A-Associated p300 ProteinEp300 protein, mouseExtracellular Signal-Regulated MAP KinasesGlucagon-Like Peptide 1GlucoseHistone DeacetylasesInsulinMitogen-Activated Protein KinasesNFATC Transcription Factorsp38 Mitogen-Activated Protein KinasesRNA, MessengerTacrolimusTumor Necrosis Factor-alpha

Identifiers

PMID25496032
PMCPMC4318885
OpenAlexW2163982634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.